ABRACL在恶性肿瘤发生发展中的作用

doi:10.3760/cma.j.cn371439-20230506-00104

国际肿瘤学杂志 ›› 2023, Vol. 50 ›› Issue (9): 544-547.doi: 10.3760/cma.j.cn371439-20230506-00104

ABRACL在恶性肿瘤发生发展中的作用

叶彤彤, 吴泽宇, 席文一, 王芝微, 江晓春, 赵晨辉()

皖南医学院第一附属医院神经外科，芜湖 241000

收稿日期:2023-05-06 修回日期:2023-05-30 出版日期:2023-09-08 发布日期:2023-10-26
通讯作者: 赵晨辉 E-mail:zhaochenhui0510@sina.com
基金资助:
安徽省教育厅自然科学重点项目(2022AH051250);安徽省高校优秀科研创新团队项目(2022AH010073);芜湖市科技局应用基础研究项目(2022JC69);皖南医学院中青年研究基金(WK2021F22)

Role of ABRACL in the occurrence and development of malignant tumors

Ye Tongtong, Wu Zeyu, Xi Wenyi, Wang Zhiwei, Jiang Xiaochun, Zhao Chenhui()

Department of Neurosurgery， First Affiliated Hospital of Wannan Medical College， Wuhu 241000， China

Received:2023-05-06 Revised:2023-05-30 Online:2023-09-08 Published:2023-10-26
Contact: Zhao Chenhui E-mail:zhaochenhui0510@sina.com
Supported by:
Department of Education Natural Science Key Project of Anhui Provincial of China(2022AH051250);Excellent Scientific Research Innovation Team Project of Anhui University(2022AH010073);Applied Basic Research Project of Wuhu Science and Technology Bureau(2022JC69);Young and Middle School Research Fund of Wannan Medical College(WK2021F22)

摘要/Abstract

摘要：

ABRACL蛋白是肌动蛋白和细胞运动的调节因子，属于HSPC280家族，其保守的疏水槽可与其他蛋白相互作用，从而增强肌动蛋白动力和细胞活性。ABRACL在肿瘤组织中表达上调，与肿瘤细胞的增殖和迁移关系密切。深入了解ABRACL在肿瘤发生发展中的作用，可为ABRACL预防或逆转肿瘤进展提供新的思路和见解。

关键词: 肿瘤, 致癌作用, 细胞骨架, ABRACL

Abstract:

The ABRACL protein， the regulator of actin and cell motility， belongs to the HSPC280 family， and its conserved hydrophobic groove can interact with other proteins to facilitate actin motility and cellular activity. ABRACL is upregulated in tumor tissues and is closely linked with the proliferation and migration of tumor cells. A deeper understanding of the role of ABRACL in tumorigenesis and development may provide new ideas and insights for ABRACL to prevent or reverse tumor progression.

Key words: Neoplasms, Carcinogenesis, Cytoskeleton, ABRACL

叶彤彤, 吴泽宇, 席文一, 王芝微, 江晓春, 赵晨辉. ABRACL在恶性肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2023, 50(9): 544-547.

Ye Tongtong, Wu Zeyu, Xi Wenyi, Wang Zhiwei, Jiang Xiaochun, Zhao Chenhui. Role of ABRACL in the occurrence and development of malignant tumors[J]. Journal of International Oncology, 2023, 50(9): 544-547.

参考文献 27

[1]	Bakir B, Chiarella AM, Pitarresi JR, et al. EMT, MET, plasticity, and tumor metastasis[J]. Trends Cell Biol, 2020, 30(10): 764-776. DOI: 10.1016/j.tcb.2020.07.003. pmid: 32800658
[2]	Fares J, Fares MY, Khachfe HH, et al. Molecular principles of metastasis: a hallmark of cancer revisited[J]. Signal Transduct Target Ther, 2020, 5(1): 28. DOI: 10.1038/s41392-020-0134-x.
[3]	Hyrskyluoto A, Vartiainen MK. Regulation of nuclear actin dynamics in development and disease[J]. Curr Opin Cell Biol, 2020, 64: 18-24. DOI: 10.1016/j.ceb.2020.01.012. pmid: 32088545
[4]	Li J, Chen H. Actin-binding Rho activating C-terminal like (ABRACL) transcriptionally regulated by MYB proto-oncogene like 2 (MYBL2) promotes the proliferation, invasion, migration and epithelial-mesenchymal transition of breast cancer cells[J]. Bioengineered, 2022, 13(4): 9019-9031. DOI: 10.1080/21655979.2022.2056821. pmid: 35341461
[5]	Lin J, Zhou T, Wang J. Solution structure of the human HSPC280 protein[J]. Protein Sci, 2011, 20(1): 216-223. DOI: 10.1002/pro.548. pmid: 21082705
[6]	Pang TL, Chen FC, Weng YL, et al. Costars, a dictyostelium protein similar to the C-terminal domain of STARS, regulates the actin cytoskeleton and motility[J]. J Cell Sci, 2010, 123(Pt 21): 3745-3755. DOI: 10.1242/jcs.064709.
[7]	Hsiao BY, Chen CH, Chi HY, et al. Human costars family protein ABRACL modulates actin dynamics and cell migration and associates with tumorigenic growth[J]. Int J Mol Sci, 2021, 22(4): 2037. DOI: 10.3390/ijms22042037.
[8]	Hamidi H, Ivaska J. Every step of the way: integrins in cancer progression and metastasis[J]. Nat Rev Cancer, 2018, 18(9): 533-548. DOI: 10.1038/s41568-018-0038-z. pmid: 30002479
[9]	Novikov NM, Zolotaryova SY, Gautreau AM, et al. Mutational drivers of cancer cell migration and invasion[J]. Br J Cancer, 2021, 124(1): 102-114. DOI: 10.1038/s41416-020-01149-0.
[10]	Ghouzlani A, Kandoussi S, Tall M, et al. Immune checkpoint inhibitors in human glioma microenvironment[J]. Front Immunol, 2021, 12: 679425. DOI: 10.3389/fimmu.2021.679425.
[11]	Youssef G, Miller JJ. Lower grade gliomas[J]. Curr Neurol Neurosci Rep, 2020, 20(7): 21. DOI: 10.1007/s11910-020-01040-8.
[12]	Liu B, Guan Y, Wang M, et al. ABRACL as a potential prognostic biomarker and correlates with immune infiltration in low-grade gliomas[J]. Interdiscip Neurosurg, 2022, 30: 101618. DOI: 10.1016/j.inat.2022.101618.
[13]	Brägelmann J, Lorenz C, Borchmann S, et al. MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG -Ⅰ[J]. Nat Commun, 2021, 12(1): 5505. DOI: 10.1038/s41467-021-25728-8. pmid: 34535668
[14]	Ben-Dror J, Shalamov M, Sonnenblick A. The history of early breast cancer treatment[J]. Genes (Basel), 2022, 13(6): 960. DOI: 10.3390/genes13060960.
[15]	Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis[J]. Trends Cell Biol, 2019, 29(3): 212-226. DOI: 10.1016/j.tcb.2018.12.001. pmid: 30594349
[16]	Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J]. Chin Med J (Engl), 2021, 134(7): 783-791. DOI: 10.1097/CM9.0000000000001474.
[17]	曹莎莎, 段丽娟, 周福有. 基于TCGA分析ABRACL在食管癌组织中的表达及机制[J]. 河南医学研究, 2021, 30(34): 6340-6344. DOI: 10.3969/j.issn.1004-437X.2021.34.002.
[18]	Wang D, Liu H, Ren C, et al. High expression of ABRACL is associated with tumorigenesis and affects clinical outcome in gastric cancer[J]. Genet Test Mol Biomarkers, 2019, 23(2): 91-97. DOI: 10.1089/gtmb.2018.0195.
[19]	Fan S, Chen P, Li S. miR-145-5p inhibits the proliferation, migration, and invasion of esophageal carcinoma cells by targeting ABRACL[J]. Biomed Res Int, 2021, 2021: 6692544. DOI: 10.1155/2021/6692544.
[20]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
[21]	Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer[J]. CA Cancer J Clin, 2021, 71(3): 264-279. DOI: 10.3322/caac.21657.
[22]	Zhao Y, Li S, Childs EE, et al. Activation of pro-death Bcl-2 family proteins and mitochondria apoptosis pathway in tumor necrosis factor-α-induced liver injury[J]. J Biol Chem, 2001, 276(29): 27432-27440. DOI: 10.1074/jbc.M102465200. pmid: 11369777
[23]	Ura B, Monasta L, Arrigoni G, et al. A proteomic approach for the identification of biomarkers in endometrial cancer uterine aspirate[J]. Oncotarget, 2017, 8(65): 109536-109545. DOI: 10.18632/oncotarget.22725.
[24]	Deutsch EW, Omenn GS, Sun Z, et al. Advances and utility of the human plasma proteome[J]. J Proteome Res, 2021, 20(12): 5241-5263. DOI: 10.1021/acs.jproteome.1c00657. pmid: 34672606
[25]	Saghaleyni R, Sheikh Muhammad A, Bangalore P, et al. Machine learning-based investigation of the cancer protein secretory pathway[J]. PLoS Comput Biol, 2021, 17(4): e1008898. DOI: 10.1371/journal.pcbi.1008898.
[26]	Zygulska AL, Pierzchalski P. Novel diagnostic biomarkers in colo-rectal cancer[J]. Int J Mol Sci, 2022, 23(2): 852. DOI: 10.3390/ijms23020852.
[27]	Battaglia RA, Delic S, Herrmann H, et al. Vimentin on the move: new developments in cell migration[J]. F1000Res, 2018, 7: F1000 Faculty Rev-1796. DOI: 10.12688/f1000research.15967.1.

ABRACL在恶性肿瘤发生发展中的作用

Role of ABRACL in the occurrence and development of malignant tumors

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 27

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.